Skip to Content
Merck
  • Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement.

Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement.

Infection and immunity (2015-01-07)
Marta Putrinš, Karin Kogermann, Eliisa Lukk, Markus Lippus, Vallo Varik, Tanel Tenson
ABSTRACT

Uropathogenic strains of Escherichia coli (UPEC) are the major cause of bacteremic urinary tract infections. Survival in the bloodstream is associated with different mechanisms that help to resist serum complement-mediated killing. While the phenotypic heterogeneity of bacteria has been shown to influence antibiotic tolerance, the possibility that it makes cells refractory to killing by the immune system has not been experimentally tested. In the present study we sought to determine whether the heterogeneity of bacterial cultures is relevant to bacterial targeting by the serum complement system. We monitored cell divisions in the UPEC strain CFT073 with fluorescent reporter protein. Stationary-phase cells were incubated in active or heat-inactivated human serum in the presence or absence of different antibiotics (ampicillin, norfloxacin, and amikacin), and cell division and complement protein C3 binding were measured by flow cytometry and immunofluorescence microscopy. Heterogeneity in the doubling times of CFT073 cells in serum enabled three phenotypically different subpopulations to be distinguished, all of them being recognized by the C3 component of the complement system. The population of rapidly growing cells resists serum complement-mediated lysis. The dominant subpopulation of cells with intermediate growth rate is susceptible to serum. The third population, which does not resume growth upon dilution from stationary phase, is simultaneously protected from serum complement and antibiotics.

MATERIALS
Product Number
Brand
Product Description

Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Glycerol solution, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Ampicillin sodium salt, BioXtra, suitable for cell culture
Supelco
Chloramphenicol, VETRANAL®, analytical standard
Supelco
Norfloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
Glycerol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Ampicillin sodium salt
Sigma-Aldrich
Chloramphenicol, meets USP testing specifications
Sigma-Aldrich
Glycerol, BioXtra, ≥99% (GC)
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
Sigma-Aldrich
Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerol, for molecular biology, ≥99.0%
Sigma-Aldrich
Chloramphenicol, BioReagent, suitable for plant cell culture
Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Ampicillin sodium salt, powder or crystals, BioReagent, suitable for cell culture
Sigma-Aldrich
Chloramphenicol, ≥98% (HPLC)
Sigma-Aldrich
Glycerol, ≥99.5%
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycerol, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
Glycerol, puriss., anhydrous, 99.0-101.0% (alkalimetric)
Supelco
Glycerol, analytical standard
Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Ampicillin Sodium, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ampicillin sodium, United States Pharmacopeia (USP) Reference Standard
Norfloxacin, European Pharmacopoeia (EP) Reference Standard
Amikacin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Glycerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Glycerol, ACS reagent, ≥99.5%